Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...

Calcitonin gene-related peptide (CGRP) inhibitors -- a group of drugs commonly used to treat migraine -- were associated with decreased rates of acne and rosacea compared with drugs that did not ...

The first three calcitonin gene-related peptide (CGRP) inhibitors approved for prevention of migraine displayed a reassuring safety profile in real-world clinical practice during the first 6 months ...

Initiation of a CGRP inhibitor was associated with a higher rate of the composite primary outcome than noninitiation (adjusted hazard ratio [aHR], 1.3; 95% CI, 1.1-1.45). It was also linked to an ...

EMERGE was an open-label trial that enrolled migraine patients who were undergoing treatment with an oral CGRP inhibitor for at least one month and experiencing an inadequate response to the oral CGRP ...

A surgeon is seen here in an undated stock photo. automation A new study shows that FDA-approved oral migraine drug atogepant is effective for relieving difficult-to-treat "medication overuse ...

CHATHAM, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a research ...

Slate Medicines’ antibody drug is designed to block PACAP, a protein associated with migraines.

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP ...

Add Yahoo as a preferred source to see more of our stories on Google. For Cherise Irons, chocolate, red wine and aged cheeses are dangerous. So are certain sounds, perfumes and other strong scents, ...

--Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system disorders, today announced that the EMERGE Phase 3 trial of SYMBRAVO ® in patients ...